Solara Active Pharma Sciences Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Solara Q2'26 Performance".
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Solara Active Pharma Sciences reported a weak Q2 FY26, with revenue falling 10% year-on-year to INR 3,140 Mn and 2% sequentially. EBITDA dropped sharply by 43% YoY to INR 352 Mn, with margins compressing to 11.3% from 17.7% in Q2 FY25. The company slipped into a net loss of INR 101 Mn (EPS of -INR 2.36) compared to a profit of INR 79 Mn a year ago. Management attributed the poor performance to an unscheduled shutdown at the Mangalore facility for upgradation, which led to delayed deliveries of high-margin products worth INR 300-350 Mn and one-time costs of about INR 40 Mn. On the positive side, gross debt was reduced by INR 1,527 Mn to INR 6,233 Mn, and the company is progressing on a demerger of its CRAMS and Polymers business into a new entity called Synthix Global Pharma Solutions to unlock value.
Short-term negative for shareholders as the company posted a loss and saw steep EBITDA margin compression, though management is framing the issues as temporary. The ongoing debt reduction, rights issue, and planned demerger are structural positives that could support the stock if execution improves in coming quarters.